Old Web
English
Sign In
Acemap
>
Paper
>
97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407
97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407
2021
Andrew G. Robinson
David Vicente
Ali Tafreshi
H. Soto Parra
Julien Mazieres
Irfan Cicin
B. Medgyasszay
Jeronimo Rodriguez-Cid
Isamu Okamoto
Sung-Yun Lee
Rodryg Ramlau
V. Vladimirov
Ying Cheng
Balazs Halmos
C.C. Liu
P. Schwarzenberger
Bilal Piperdi
Luis Paz-Ares
Keywords:
first line
Pembrolizumab
Internal medicine
Medicine
Oncology
Chemotherapy
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
4
Citations
NaN
KQI
[]